• Home
  • News
  • Coins2Day 500
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
    • Great Place To Work
  • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Success
    • Future Of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Analytics
  • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Home
  • News
  • Coins2Day 500
    • Coins2Day 500
    • Coins2Day Global 500
    • Coins2Day 500 Europe
    • Coins2Day China 500
    • Coins2Day SEA 500
    • Great Place To Work
  • Tech
    • Tech
    • AI
    • Innovation
    • Cybersecurity
  • Finance
    • Finance
    • Personal Finance
    • Real Estate
    • Economy
    • Investing
    • Banking
    • Crypto
  • Leadership
    • Leadership
    • Success
    • Future Of Work
    • Workplace Culture
    • C-Suite
    • CEO Initiative
  • Lifestyle
    • Lifestyle
    • Arts & Entertainment
    • Travel & Leisure
    • Health
    • Well
    • Education
  • Rankings
    • Rankings
    • Analytics
  • Multimedia
    • Multimedia
    • Live Media
    • Magazine
    • Newsletters
    • Video
    • Podcasts
  • Asia
  • Europe
  • Analytics
  1. home
  1. home
  2. Eli Lilly

Eli Lilly

Page 7 of 7

Johns Hopkins Hospital Continues Cancer Research And Treatment
Health

These Are the Most Promising Experimental Cancer Drugs

By Market Analyst
June 9, 2016
General Views of Eli Lilly & Co.
Health

Pharma Giant Eli Lilly Wants to Launch 20 New Drugs by 2023

By News Correspondent
May 24, 2016
The CEO of Valeant Pharmaceuticals has suggested that Allergan is fat, overstaffed and ripe for big
Health

Allergan Struck a $3.3 Billion Alzheimer’s Drug Deal Right After Its Pfizer Merger Collapsed

By Financial Writer
April 7, 2016
U.S. Multinationals in Puerto Rico
Health

Eli Lilly Just Lost the Latest Round in its Patent Battle

By Research Team
February 12, 2016
J. Michael Pearson, chief executive officer, Valeant Pharmaceuticals International Inc., speaks during the Bloomberg Economic Series: Canada 2015 in Toronto, Ontario Thursday May 21/2015. (Photo by Kevin Van Paassen/Bloomberg)
Finance

Biotech Stocks Crashed and Nobody Knows Why

By Digital Assets Editor
January 29, 2016
U.S. Multinationals in Puerto Rico
Finance

Eli Lilly’s Outlook for 2016 Disappoints

By Editorial Team
January 5, 2016
CHINA-ECONOMY-STOCKS
Retail

China Stocks and December Auto Sales–5 Things to Know Today

By Investment Desk
January 5, 2016
Prediction: A New Drug Will Soon Offer Hope in the Alzheimer’s Fight
Health

Prediction: A New Drug Will Soon Offer Hope in the Alzheimer’s Fight

By Tech Reporter
December 1, 2015
U.S. Multinationals in Puerto Rico
Health

FDA Approves New Eli Lilly Drug for Advanced Lung Cancer

By Contributing Writer
November 24, 2015
Eli Lilly & Co's Zyprexa schizophrenia drug is pictured in a
Finance

Eli Lilly adds one more to roster of failed heart drugs, and it won’t be the last

By Research Team
October 12, 2015
General Views of Eli Lilly & Co.
Health

Why drug maker Eli Lilly’s stock price is down big today

By Editorial Team
October 12, 2015
Apple Worldwide Developers Conference Opens In San Francisco
Features

Apple, Greek banks, and earnings — 5 things to know this week

By Senior Editor
July 19, 2015

Most Popular

  • AI
    Elon Musk says that in 10 to 20 years, work will be optional and money will be irrelevant thanks to AI and robotics
    By Crypto Correspondent
  • Economy
    One of the world’s most popular economists on why AI is ‘undoubtedly going to crash’: It’s built off ‘digital...
    By Contributing Writer
  • Economy
    Trump's retreats on tariffs have already wiped out $800 billion of expected deficit reduction, CBO estimates
    By Research Team
Rankings
  • 100 Best Companies
  • Coins2Day 500
  • Global 500
  • Coins2Day 500 Europe
  • Most Powerful Women
  • Future 50
  • World’s Most Admired Companies
  • See All Rankings
Sections
  • Finance
  • Leadership
  • Success
  • Tech
  • Asia
  • Europe
  • Environment
  • Coins2Day Crypto
  • Health
  • Retail
  • Lifestyle
  • Politics
  • Newsletters
  • Magazine
  • Features
  • Commentary
  • MPW
  • CEO Initiative
  • Conferences
  • Personal Finance
  • Education
Customer Support
  • Frequently Asked Questions
  • Customer Service Portal
  • Privacy Policy
  • Terms of Use
  • Single Issues for Purchase
  • International Print
Commercial Services
  • Advertising
  • Coins2Day Brand Studio
  • Coins2Day Analytics
  • Coins2Day Conferences
  • Business Development
About Us
  • About Us
  • Editorial Calendar
  • Press Center
  • Work at Coins2Day
  • Diversity and Inclusion
  • Terms and Conditions
  • Site Map

© 2025 Coins2Day Media IP Limited. All Rights Reserved. Use of this site constitutes acceptance of our Terms of Use and Privacy Policy | CA Notice at Collection and Privacy Notice | Do Not Sell/Share My Personal Information
FORTUNE is a trademark of Coins2Day Media IP Limited, registered in the U.S. and other countries. FORTUNE may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.